These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3729990)

  • 1. Effect of methylated bepridil on slow action potentials in cardiac muscle and vascular smooth muscle.
    Wahler GM; Doane JD; Ousterhout JM; Sperelakis N; Lamar JC; Busch N; Biswas JC; Rogers TB
    Biochem Pharmacol; 1986 Jul; 35(14):2337-43. PubMed ID: 3729990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bepridil blockade of Ca2+-dependent action potentials in vascular smooth muscle of dog coronary artery.
    Harder DR; Sperelakis N
    J Cardiovasc Pharmacol; 1981; 3(4):906-14. PubMed ID: 6167820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of bepridil and verapamil on isolated coronary and systemic vascular and cardiac muscle.
    Campbell JK; Marshall RJ; Winslow E
    Eur J Pharmacol; 1982 Dec; 86(2):217-28. PubMed ID: 6984392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bepridil hydrochloride alters potential-dependent and receptor-operated calcium channels in vascular smooth muscle of rabbit aorta.
    Flaim SF; Ratz PH; Swigart SC; Gleason MM
    J Pharmacol Exp Ther; 1985 Jul; 234(1):63-71. PubMed ID: 2409274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the calcium antagonists bepridil (CERM-1978) and verapamil on Ca++-dependent slow action potentials in frog skeletal muscle.
    Kerr LM; Sperelakis N
    J Pharmacol Exp Ther; 1982 Jul; 222(1):80-6. PubMed ID: 6979625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of the bepridil-induced vasodilation of the rabbit mesenteric artery.
    Suzuki H; Itoh T; Kuriyama H
    J Pharmacol Exp Ther; 1985 Dec; 235(3):749-56. PubMed ID: 3878404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of calcium antagonists.
    Schwartz A; Matlib MA; Balwierczak J; Lathrop DA
    Am J Cardiol; 1985 Mar; 55(7):3C-7C. PubMed ID: 3872055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bepridil and of its quaternary derivative on rat tail artery.
    Schaeffer P; Baissat J; Dureng G; Lamar JC; Stoclet JC
    Eur J Pharmacol; 1986 Apr; 123(1):155-9. PubMed ID: 3486771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bepridil (CERM-1978) blockade of action potentials in cultured rat aortic smooth muscle cells.
    Mras S; Sperelakis N
    Eur J Pharmacol; 1981 Apr; 71(1):13-9. PubMed ID: 6972312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of bepridil on the electrophysiological properties of guinea-pig ventricular muscles.
    Anno T; Furuta T; Itho M; Kodama I; Toyama J; Yamada K
    Br J Pharmacol; 1984 Apr; 81(4):589-97. PubMed ID: 6609738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bepridil block of cardiac calcium and sodium channels.
    Yatani A; Brown AM; Schwartz A
    J Pharmacol Exp Ther; 1986 Apr; 237(1):9-17. PubMed ID: 2420970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of bepridil on membrane currents of rabbit sinoatrial node cells.
    Kotake H; Igawa O; Miyamoto J; Hasegawa J; Kosaka T; Furuse T; Mashiba H
    Arzneimittelforschung; 1987 Apr; 37(4):424-7. PubMed ID: 3496889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative electrophysiological effects of disopyramide and bepridil on rabbit atrial, papillary, and Purkinje tissue: modification by reduced extracellular potassium.
    Winslow E; Campbell JK; Marshall RJ
    J Cardiovasc Pharmacol; 1986; 8(6):1208-16. PubMed ID: 2434748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium blocking properties of piprofurol.
    Pourrias B; Huerta F; Santamaria R; Bowe C
    Arch Int Pharmacodyn Ther; 1985 Apr; 274(2):223-39. PubMed ID: 4026458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological properties of SD-3211, a novel putative Ca2+ antagonist, in isolated guinea pig and rabbit hearts.
    Miyawaki N; Furuta T; Shigei T; Yamauchi H; Iso T
    J Cardiovasc Pharmacol; 1990 Nov; 16(5):769-75. PubMed ID: 1703599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Ca2+ agonist (Bay K 8644) enhances and induces cardiac slow action potentials.
    Wahler GM; Sperelakis N
    Am J Physiol; 1984 Aug; 247(2 Pt 2):H337-40. PubMed ID: 6205600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcium channel blocking properties of amlodipine in vascular smooth muscle and cardiac muscle in vitro: evidence for voltage modulation of vascular dihydropyridine receptors.
    Burges RA; Gardiner DG; Gwilt M; Higgins AJ; Blackburn KJ; Campbell SF; Cross PE; Stubbs JK
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):110-9. PubMed ID: 2434785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ca2+-dependent slow action potentials in normal and dystrophic mouse skeletal muscle.
    Kerr LM; Sperelakis N
    Am J Physiol; 1983 Nov; 245(5 Pt 1):C415-22. PubMed ID: 6605692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic and electrophysiological actions of flecainide, bepridil and amiodarone on isolated heart preparations during controlled hypoxia.
    Dietrich H; Borchard U; Hafner D; Hirth C
    Arch Int Pharmacodyn Ther; 1985 Apr; 274(2):267-82. PubMed ID: 3875326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bepridil blunts the shortening of action potential duration caused by metabolic inhibition via blockade of ATP-sensitive K(+) channels and Na(+)-activated K(+) channels.
    Li Y; Sato T; Arita M
    J Pharmacol Exp Ther; 1999 Nov; 291(2):562-8. PubMed ID: 10525072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.